Alterity to Present Phase 2 Data and Phase 3 Plan at Virtual KOL Event
Alterity Therapeutics will host a virtual key opinion leader event on April 28 (US) and April 29 (Australia) to discuss its lead candidate ATH434, reviewing Phase 2 data and outlining Phase 3 trial plans for Multiple System Atrophy. Speakers include Roy Freeman, MD, Daniel Claassen, MD, and CEO David Stamler.
1. Event Overview
Alterity Therapeutics will host a webcast on April 28 at 10:00 a.m. PT/1:00 p.m. ET for US participants and on April 29 at 3:00 a.m. AEST for Australian participants. The virtual event agenda includes an overview of ATH434, a review of the Multiple System Atrophy treatment landscape, Phase 2 data discussions, and high-level Phase 3 planning.
2. ATH434 Program Updates
ATH434 is Alterity's potential first-in-class, disease-modifying therapy for MSA that demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive signals in an open-label extension. The event will present new analyses of biomarker and clinical outcome data and outline the design parameters, endpoints, and timelines for the upcoming Phase 3 pivotal study.
3. Key Opinion Leader Presentations
The webcast will feature Roy Freeman, MD, Harvard Medical School neurologist specializing in autonomic disorders; Daniel Claassen, MD, MS, Vanderbilt University expert in movement disorders and MSA; and Alterity CEO David Stamler, MD, who will moderate discussions on unmet needs, trial design, and commercial outlook for ATH434.